Lead Plaintiff Deadline is Approaching - Act Now

Edwards Lifesciences Corp.® Class Action

Patel v. Edwards Lifesciences Corporation et al.

Edwards Lifesciences Corp.®

NASDAQ: EW

Class Period : 02/06/2024 - 07/24/2024

Lead Plaintiff Motion Deadline: 12/13/2024

Edwards Lifesciences Corp.® Shareholder Class Action

Edwards Lifesciences Corp.® (Edwards®) shareholders have filed a class action lawsuit, alleging that the company made false and misleading statements about its financial performance and prospects. The lawsuit claims that Edwards misled investors about the growth of its core product, the Transcatheter Aortic Valve Replacement (TAVR) platform, and failed to disclose important information contributing to a sharp decline in its stock price.

Alleged Misstatements and Omissions

The class action lawsuit outlines several key allegations regarding Edwards' misstatements:

  • Overstated Commitment to TAVR: Edwards allegedly made false claims about its strong commitment to the TAVR platform, a key revenue driver for the company. These claims led investors to believe that the TAVR product would experience continued growth and success throughout 2024.
  • Misleading Growth Projections: Edwards also misled investors by stating that the company could capitalize on a subset of untreated patients by scaling its patient activation activities. This gave the impression that demand for TAVR would continue to rise despite challenges in the market.
  • False Claims of Significant Demand: According to the lawsuit, Edwards repeatedly claimed significant demand for TAVR in lower-penetrated markets, which was not supported by the company’s actual performance.

Impact on Edwards' Stock Price

The truth about Edwards' performance and outlook was revealed on July 24, 2024, when the company announced disappointing financial results for the second quarter of fiscal 2024. The company slashed its revenue guidance for the TAVR platform, which sent shockwaves through the market. Edwards attributed the setback to the “continued growth and expansion of structural heart therapies,” which had put pressure on hospital workflows and caused underutilization of TAVR.

It became clear that new procedures, including Edwards' own Transcatheter Mitral and Tricuspid Therapies (TMTT), were straining hospital structural heart teams, leading to TAVR's underperformance. Despite the company's ongoing claims about a significantly undertreated patient population, TAVR growth had slowed.

In addition, Edwards announced three acquisitions during the second quarter aimed at bolstering treatment alternatives to TAVR, further suggesting that the company was aware of the decelerated growth in its TAVR platform. These announcements raised concerns among investors about Edwards' future performance and market position.

Following the release of this news, Edwards’ stock price fell dramatically. From a closing price of $86.95 per share on July 24, 2024, the stock plunged to $59.70 per share on July 25, 2024, marking a 31.34% drop in just one day.

Legal Rights for Affected Shareholders

You may be eligible to join the class action lawsuit if you are a shareholder of Edwards Lifesciences Corp.® and suffered financial losses due to the company's false and misleading statements. Edwards' failure to accurately disclose the challenges faced by its TAVR platform and the potential impact on its future growth misled investors and led to significant stock price declines.

Take Action Now

If you believe Edwards' misleading statements and omissions impacted you, it is essential to act quickly. Contact our legal team for a free consultation to learn more about your rights and find out if you qualify to join the class action lawsuit.

Don’t wait—take the first step toward securing justice and compensation for your financial losses today.

image-3

Contact DiCello Levitt Today To Explore Your Legal Options

DiCello Levitt, known for its success in protecting shareholder rights, actively seeks justice for those affected by Edwards’® alleged misconduct.

If you held Edwards® stock during the class period and believe you suffered losses due to these alleged misrepresentations, you may be eligible to participate in this class action lawsuit.

Contact DiCello Levitt today to explore your legal options and understand how to join this critical effort to seek accountability and potential recovery for your investment losses. Our team is dedicated to advocating for shareholder interests and can provide you with the guidance and support needed during this process.

Take action now to protect your rights as an investor and learn more about this significant legal opportunity.

All victims affected by Edwards’® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

Find Out if You may be a Member
of the Class

Oops! We could not locate your form.

*Consent: If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form above. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit. By clicking the "SUBMIT" button, I consent to receive recurring auto dialed and/or text messages from Stock Fraud Claim, DiCello Levitt, and Tort Intake Professionals LLC or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the Stock Fraud Claim Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 27 msgs per month.

Edwards Lifesciences Corp.® Class Action

Patel v. Edwards Lifesciences Corporation et al.

Edwards Lifesciences Corp.®

NASDAQ: EW

Class Period : 02/02/2021 - 08/26/2024

Lead Plaintiff Motion Deadline: 10/29/2024

Edwards Lifesciences Corp.® Shareholder Class Action

Edwards Lifesciences Corp.® (Edwards®) shareholders have filed a class action lawsuit, alleging that the company made false and misleading statements about its financial performance and prospects. The lawsuit claims that Edwards misled investors about the growth of its core product, the Transcatheter Aortic Valve Replacement (TAVR) platform, and failed to disclose important information contributing to a sharp decline in its stock price.

Alleged Misstatements and Omissions

The class action lawsuit outlines several key allegations regarding Edwards' misstatements:

  • Overstated Commitment to TAVR: Edwards allegedly made false claims about its strong commitment to the TAVR platform, a key revenue driver for the company. These claims led investors to believe that the TAVR product would experience continued growth and success throughout 2024.
  • Misleading Growth Projections: Edwards also misled investors by stating that the company could capitalize on a subset of untreated patients by scaling its patient activation activities. This gave the impression that demand for TAVR would continue to rise despite challenges in the market.
  • False Claims of Significant Demand: According to the lawsuit, Edwards repeatedly claimed significant demand for TAVR in lower-penetrated markets, which was not supported by the company’s actual performance.

Impact on Edwards' Stock Price

The truth about Edwards' performance and outlook was revealed on July 24, 2024, when the company announced disappointing financial results for the second quarter of fiscal 2024. The company slashed its revenue guidance for the TAVR platform, which sent shockwaves through the market. Edwards attributed the setback to the “continued growth and expansion of structural heart therapies,” which had put pressure on hospital workflows and caused underutilization of TAVR.

It became clear that new procedures, including Edwards' own Transcatheter Mitral and Tricuspid Therapies (TMTT), were straining hospital structural heart teams, leading to TAVR's underperformance. Despite the company's ongoing claims about a significantly undertreated patient population, TAVR growth had slowed.

In addition, Edwards announced three acquisitions during the second quarter aimed at bolstering treatment alternatives to TAVR, further suggesting that the company was aware of the decelerated growth in its TAVR platform. These announcements raised concerns among investors about Edwards' future performance and market position.

Following the release of this news, Edwards’ stock price fell dramatically. From a closing price of $86.95 per share on July 24, 2024, the stock plunged to $59.70 per share on July 25, 2024, marking a 31.34% drop in just one day.

Legal Rights for Affected Shareholders

You may be eligible to join the class action lawsuit if you are a shareholder of Edwards Lifesciences Corp.® and suffered financial losses due to the company's false and misleading statements. Edwards' failure to accurately disclose the challenges faced by its TAVR platform and the potential impact on its future growth misled investors and led to significant stock price declines.

Take Action Now

If you believe Edwards' misleading statements and omissions impacted you, it is essential to act quickly. Contact our legal team for a free consultation to learn more about your rights and find out if you qualify to join the class action lawsuit.

Don’t wait—take the first step toward securing justice and compensation for your financial losses today.

image-3

Contact DiCello Levitt Today To Explore Your Legal Options

DiCello Levitt, known for its success in protecting shareholder rights, actively seeks justice for those affected by Edwards’® alleged misconduct.

If you held Edwards® stock during the class period and believe you suffered losses due to these alleged misrepresentations, you may be eligible to participate in this class action lawsuit.

Contact DiCello Levitt today to explore your legal options and understand how to join this critical effort to seek accountability and potential recovery for your investment losses. Our team is dedicated to advocating for shareholder interests and can provide you with the guidance and support needed during this process.

Take action now to protect your rights as an investor and learn more about this significant legal opportunity.

All victims affected by Edwards’® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

100% Free & Secure Case Evaluations

Answer a few basic questions to get started

We'll ask specific questions to understand the situation, damage risk, and other vital information to help determine the next steps.

Receive a confidential evaluation

A qualified legal team led by a Financial Products Litigation attorney will consider the facts of your case.

Edwards’® Investors may have grounds to pursue legal action and financial recovery of damages.

This website offers general information only and is not legal or investment advice. This advertisement is not associated with any government agency.

www.stockfraudclaim.com is the property of Shield Legal LLC. 5170 Badura Ave Las Vegas, NV 89118

Participating law firm: DiCello Levitt LLP, 10 North Dearborn Street Sixth Floor Chicago, IL 60602. For additional terms, disclaimers, and conditions, please visit https://dicellolevitt.com/privacy-policy/

This website is not part of the Facebook website or Facebook, Inc., and it is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of Facebook, Inc.

ATTORNEY ADVERTISING. This Website does not provide investment, legal, or medical advice. Every case is evaluated on its facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Stock Fraud Claim does not itself provide legal services. Cases will be referred to third-party attorneys and law firms.  Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement, or dramatization and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyer's credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under 13 ("Children").

NO ATTORNEY-CLIENT RELATIONSHIP. Use of this website, including sending or receiving information through it, does not establish an attorney-client relationship, nor is any non-passworded information considered privileged or confidential. No class has been certified.  Until a case is filed and a class is certified, you are not represented by counsel unless you retain one.  You may select counsel of your choice.  An attorney-client relationship with DiCello Levitt is established only by an express written agreement signed by DiCello Levitt to represent you.

Attorney Advertising.  Prior results do not guarantee a similar outcome.

Privacy Policy | Terms and Conditions | CCPA Privacy Notice | Do Not Sell My Info

©2024 Stock Fraud Claim. All Rights Reserved